Pharmacokinetics
The metabolism of PRISTIQ is independent of the CYP2D6 pathway in the liver1
PRISTIQ demonstrated consistent pharmacokinetics regardless of CYP2D6 metabolizer status.1,2
Effects on CYP2D6 and CYP3A41
- In vitro studies showed minimal inhibitory effect on CYP2D61
- Clinical studies have shown that PRISTIQ does not have a clinically relevant effect on levels of a CYP2D6-metabolized drug when coadministered1
- PRISTIQ has a low potential for CYP2D6-mediated drug-drug interactions1
- In vitro, PRISTIQ does not inhibit or induce the CYP3A4 isozyme1
- In clinical studies, at a dose of 400 mg (8 times the recommended therapeutic dose)1:
Clinical Pharmacology of PRISTIQ1
Important Treatment Considerations
- PRISTIQ must not be used concomitantly with an MAOI or within 14 days of stopping an MAOI. Allow 7 days after stopping PRISTIQ before starting an MAOI.
- Development of a potentially life-threatening serotonin syndrome may occur with SNRIs and SSRIs, including PRISTIQ, particularly with concomitant use of serotonergic drugs, including triptans, and with drugs that impair the metabolism of serotonin (including MAOIs). If concomitant use is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases. Concomitant use of PRISTIQ with serotonin precursors is not recommended.
- SSRIs and SNRIs, including PRISTIQ, may increase the risk of bleeding events. Concomitant use of aspirin, NSAIDs, warfarin, and other anticoagulants may add to this risk.
Find details on PRISTIQ Dosing and Administration
239739-01

